Exelixis (EXEL) Cash from Operations Growth (1y) (2011 - 2026)
Exelixis (EXEL) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - | - |
| 4 | BeOne Medicines | 471.47 Bn | 466.67 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.76 Bn | 114.52 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.15 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - | - |
| 8 | Argenx Se | 55.77 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.45 Bn | 37.45 Bn | - | - |
| 10 | Exelixis | 14.47 Bn | 13.70 Bn | 590.86 Mn | 19.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 19.11% |
| Jan 2, 2026 | 38.81% |
| Oct 3, 2025 | 7.00% |
| Jul 4, 2025 | -59.02% |
| Apr 4, 2025 | 207.22% |
| Jan 3, 2025 | 2,172.85% |
| Sep 27, 2024 | 131.19% |
| Jun 28, 2024 | -1.18% |
| Mar 29, 2024 | -18.47% |
| Dec 29, 2023 | -85.66% |
| Sep 29, 2023 | 6.63% |
| Jun 30, 2023 | 288.62% |
| Mar 31, 2023 | -42.86% |
| Dec 30, 2022 | -23.60% |
| Sep 30, 2022 | 32.13% |
| Jul 1, 2022 | -82.85% |
| Apr 1, 2022 | 273.56% |
| Dec 31, 2021 | 160.30% |
| Apr 2, 2021 | -29.48% |
| Apr 3, 2020 | -65.30% |